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INTRODUCTION
Nitric oxide (NO), a crucial regulator
of vasodilation, immunity, and neuro-
transmission, is also involved in regulat-
ing the balance between proliferation
and differentiation in several develop-
mental and differentiation settings (1-7).
In several instances, this action of NO is
based on its antiproliferative properties,
such that suppression of NO synthase
(NOS) activity by pharmacologic or ge-
netic means increases the number of di-
viding cells in a tissue and delays or
hinders differentiation (2-4,6,8-14). NO
can act in both autocrine and paracrine
signaling modes, activating soluble
guanylate cyclase, combining with reac-
tive oxygen species, modifying proteins,
and inducing both short- and long-term
signaling cascades (1,5,7,15-17).
In the hematopoietic system, NO con-
tributes to the regulation of hematopoi-
etic stem and progenitor cells in the bone
marrow; exposure of mice to NOS in-
hibitors, either directly or after irradia-
tion and bone marrow transplantation,
increases the number of stem and pro-
genitor cells in the bone marrow (18).
Moreover, in the transplantation model,
this increase is followed by a transient
increase in the number of neutrophils in
the peripheral blood (18), indicating that
modulation of NOS activity may be used
for therapeutic intervention.
There are three NOS genes in the
mammalian genome, coding for the neu-
ronal, endothelial, and inducible iso-
forms of NOS (nNOS, eNOS, and iNOS,
respectively), and mRNA of each NOS
isoform can be reliably detected in
mouse bone marrow (18). Furthermore,
nNOS mRNA has been detected in neu-
trophils (19-22), eNOS mRNA has been
detected in lymphocytes, megakary-
ocytes, and platelets (19,23), and iNOS
mRNA has been found in megakary-
ocytes, eosinophils, and unstimulated
monocytes (21,24).
Although the action of NO in the
hematopoietic system can be readily
demonstrated (18,25-29), neither the
contribution of individual NOS isoforms
nor their mode of action (autocrine vs.
paracrine) is understood. We show here
that NOS proteins are expressed in bone
marrow stroma, that expression of the
nNOS isoform strongly correlates with
the ability of a panel of stromal cell
lines to support hematopoietic stem and
early progenitor cells in vitro, and that
genetic inactivation of the nNOS gene
increases the number of colonies that
can be generated from bone marrow
and spleen. Our results suggest that
nNOS acts as a paracrine effector to reg-
ulate hematopoiesis.
MATERIALS AND METHODS
Animals
We used 6- to 12-week-old C57Bl/6
female and male mice (Jackson Laborato-
ries, Bar Harbor, ME, USA, or Taconic
Farms, Germantown, NY, USA). Mice
with genetically inactivated eNOS gene
(B6.129 P2-NOS3tm1Unc) and iNOS gene
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(B6.129P2-NOS2tm1Lau) were purchased
from Jackson Laboratories. Generation of
nNOS-null mutant mice, lacking exon 6 of
the nNOS gene (nNOSKOex6 mice), has
been described (10). All mice were bred
and maintained at the Cold Spring Har-
bor Laboratory Animal Care Facility in
microisolator cages. Wild-type, iNOS-/-,
and eNOS-/- mice were provided with au-
toclaved standard diet. nNOS-/- mice were
provided with autoclaved liquid diet. All
mice received acidified water ad libitum.
Isolation of Bone Marrow, Spleen, and
Fetal Liver Cells
Animals were killed by cervical dislo-
cation. Bone marrow cells were isolated
from femurs and tibias by repeatedly
flushing the bones with Iscove’s modi-
fied DMEM medium (Iscove’s MDM)
(Invitrogen) supplemented with 2% heat-
inactivated fetal bovine serum (FBS)
using a 1-mL syringe and a 21G needle.
The cells were then passed three times
through a 26G needle. Spleens were
minced with fine scissors in Iscove’s
MDM containing 2% FBS. Cell aggre-
gates were disrupted by drawing the cell
suspension up and down nine times
through a blunt 18G needle (StemCell
Technologies) using a 3-mL syringe, fol-
lowed by three to four times with a 21G
needle. The resulting suspension was fil-
tered using a 40-µm cell strainer (Falcon).
For isolation of e14 fetal liver cells, preg-
nant female mice after anesthesia were
perfused with Hanks solution, and em-
bryos were isolated. Livers were dis-
sected from e14 embryos or newborn p1
mice and minced with fine scissors in
Hanks solution. After centrifugation
(160 g, 10 min), cells were resuspended
in 1 mL collagenase-containing Liver
Digest solution (Gibco) and incubated
for 10 min at 37°C and then EDTA was
added to final concentration 5 mM for
collagenase inactivation. The cell suspen-
sion was filtered using a 40-µm cell
strainer (Falcon). The aliquots of cell
suspensions were diluted with 3% acetic
acid with Methylene Blue (StemCell
Technologies), and nuclear cells were
counted using a hemocytometer.
Primary Cell Cultures
For primary cell cultures, bone marrow
or spleen cells were seeded on 35-mm
plates (5 × 106 per plate) in Myelocult
medium supplemented with 1 µM hy-
drocortisone (both StemCell Technolo-
gies) and cultured at 33°C in a humidified
5% CO2 atmosphere for 14 days. One-half
of the culture medium was replaced weekly
with fresh MyeloCult-hydrocortisone
medium. For the analysis of NOS expres-
sion in bone marrow stroma, the cells
were grown for 3 weeks until they
reached 85% to 95% confluence and then
exposed directly on the plate to 15 Gy γ
irradiation (Marc I irradiator with ce-
sium-137 source). After irradiation, cell
cultures were further maintained for at
least 4 days to remove destroyed
hematopoietic cells. For the measure-
ment of the endogenous NO production,
irradiated stromal cells were kept in cul-
ture, and half of the media was replaced
weekly. Isolated liver cells were seeded
on 100-mm plates (10 × 106 per plate) in
the media containing 50% Myelocult,
35% α-MEM, 15% FBS, and 1 µM hydro-
cortisone and cultured at 37°C in a hu-
midified 5% CO2 atmosphere. Half of the
culture medium was replaced weekly.
Stromal Cell Lines
Stromal cell lines from were grown in
DMEM supplemented with 10% FBS and
50 µm β-mercaptoethanol at 33°C in a
humidified 5% CO2 atmosphere.
Quantification of Committed
Progenitors (CFCs)
All reagents for the analyses were pur-
chased from StemCell Technologies, and
the assay was performed according to
the manufacturer’s instructions. For
colony-forming cell (CFC) quantification,
semisolid Methocult GF M3434 medium
was used. Mononuclear bone marrow
cells from femurs or spleen cells of at
least three animals of each genotype
were seeded in triplicate on 35-mm non-
adhesive plates in 1 mL of the medium at
a density of 2 × 104 and 1 × 105 cells per
plate, respectively. The cultures were
maintained for 12 d at 37°C in a humidi-
fied 5% CO2 atmosphere, and the total
number of colonies containing >50 cells
was counted using an inverted micro-
scope. To analyze the CFC content in
bone marrow or spleen primary cell cul-
tures, after 14 days of cultivation floating
hematopoietic cells were collected and
attached hematopoietic and stromal cells
were collected after treatment of cultures
with trypsin in citrate saline (StemCell
Technologies) and combined with the
floating hematopoietic cells. After wash-
ing with DMEM supplemented with 2%
FBS, the cells were differentially counted
using size discrimination criteria in a
hemocytometer chamber, seeded in
Methocult GF M3434 medium, cultured,
and analyzed as described above. In a
separate series of experiments, we ex-
amined the effect of the NO donor
SNAP, added during cultivation, and
found that both the number of colonies
and the number of cells in each colony
was decreased.
Quantification of Long-Term 
Culture-Initiating Cells
The LTC-IC assay was performed as
described (18).
Quantification of Mesenchymal Stem
Cells (CFU-F)
For colony-forming unit, fibroblast
(CFU-F) quantification in the bone mar-
row, MesenCult MSC basal medium sup-
plemented with mouse Mesenchymal
Stem Cell Stimulatory Supplements
(both from StemCell Technologies) was
used according to the manufacturer’s in-
structions. Briefly, 0.5 × 106 bone marrow
mononuclear cells from femurs of at least
three animals of each genotype were
seeded in triplicates on 35-mm adhesive
plates in 2 mL of the media and cultured
without media change for 14 days at
37°C in a humidified 5% CO2 atmos-
phere. Cells were then washed with PBS,
fixed with methanol for 5 min at room
temperature, and stained with diluted
(1:20) Giemsa staining solution (StemCell
Technologies) for 5 min. After washing,
mesenchymal cell colonies were counted
using an inverted microscope.
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Quantitation of the NOS Isoform-Specific
Transcripts
Total RNA was extracted from tissues
and cultured cells using TRIzol reagent
(Gibco) according to the manufacturer’s
instructions. The amount of NOS iso-
form-specific transcripts was quantified
using real-time RT-PCR. cDNA was syn-
thesized from 2 μg total RNA using ran-
dom hexamers and Taqman Multiscribe
reverse transcriptase (125 units) (Ap-
plied Biosystems). For negative controls,
reverse transcriptase was omitted. Di-
luted cDNA was then mixed with 2×
SYBR Green PCR Master Mix (Applied
Biosystems) including 0.3 μM both for-
ward and reverse primers and amplified
in an optical plate set in the ABI PRISM
7700 Sequence Detection System (Ap-
plied Biosystems). Primers for selective
cDNA amplification of nNOS, eNOS,
iNOS, or β-actin were designed using
Primer Express software (Applied
Biosystems) to achieve the melting tem-
perature value of 58°C to 60°C and the
amplicon size of 70 to 150 bp. Primers
are as follows:
nNOS, 5′-AAAACCTGCAAAGTCC-
TAAATCCA-3′ (forward) and 5′-CTCCT-
GATTCCCGTTGGTGT-3′ (reverse);
eNOS, 5′-GATGGGCCCTGTACCT-
CAA-3′ (forward) and 5′-GTGGGCCG-
GCTCTGTAACT-3′ (reverse);
iNOS, 5′-TCCACAGTATGTGAGGAT-
CAAAAAC-3′ (forward) and 5′-ATGTG-
GCCTTGTGGTGAAGAGT-3′ (reverse);
β-actin, 5′-CGTGAAAAGATGACCCA
GATCA-3′ (forward) and 5′-CACAGC-
CTGGATGGCTACGTA-3′ (reverse);
The amplification conditions were as
follows: 1 cycle at 95°C for 10 min, then
40 cycles at 95°C for 15 s and 60°C for
1 min. Each sample was analyzed in du-
plicate. During the amplification, the
fluorescence of each sample was de-
tected in real time, and a respective am-
plification curve was generated using
the Sequence Detection System software
(Applied Biosystems). Data from NOS
amplifications were normalized for each
sample using the Ct value (threshold
cycle number, a cycle number at which
the curve starts to rise over the back-
ground noise) for β-actin. Relative differ-
ences in the amounts of individual NOS
mRNAs between analyzed samples were
calculated.
Immunoblotting
For immunoblotting experiments,
primary monoclonal antibodies (mAbs)
against nNOS (cat. no. 31020) and eNOS
(30020) and polyclonal antibodies (pAbs)
against iNOS (32030), all from BD Trans-
duction Laboratories, were used at 1:2000,
1:1000, and 1:2000 dilutions, respectively.
mAbs against β-actin (Sigma) were used
at 1:10,000 dilution. Secondary antibod-
ies (sheep anti-mouse and goat anti-rabbit
Ig-horseradish peroxidase conjugates,
Pierce), were used at 1:25,000 dilution.
Cell suspensions or tissue homogenates
in PBS were mixed with an equal vol-
ume of 2× SDS-buffer (4% SDS, 120 mM
Tris-HCl, pH 6.8) and supplemented
with protease inhibitors (1 μg/mL apro-
tinin, 1 μg/mL leupeptin, 1 μg/mL pep-
statin, and 1 mM PMSF final concentra-
tion). Lysates were passed three times
through a 26G needle to disrupt DNA,
boiled for 4 min, and centrifuged at
16,000g for 5 min. After protein determi-
nation using BCA reagent system
(Pierce), lysates were mixed with one-
third volume of 50% glycerol containing
450 mM dithiothreitol and Bromophenol
Blue and boiled for 4 min. Gel elec-
trophoresis, membrane transfer, and
protein detection were performed as de-
scribed (30).
Determination of Nitrates/Nitrites
Nitrite and nitrate concentrations
were determined in cell culture medium
as described (31-33), using the fluores-
cent 2,3-diaminonapthalene (DAN, Fluka
88461), against nitrite and nitrate stan-
dard curves (0 to 1000 nM). For each
sample, measured in quadruplet, ni-
trates were reduced to nitrites using ni-
trate reductase (NAD(P)H: nitrate oxi-
doreductase, EC 1.7.1.2 Boehringer
Mannheim, cat. no. 981249) following
standard methods (34,35) and compared
with nitrite measurements alone. Briefly,
conditioned cell culture media and ni-
trite and nitrate standard solutions (40 µL)
were treated in a microtiter tray well
with 10 µL nitrate reductase cocktail
containing (final concentrations in the
well) 0.1 U/mL nitrate reductase, 5 µM
FAD, 1 µM NAD(P)H), 0.5 mM glucose-
6-phosphate (G-6-P), and 0.4 U/mL and
G-6-P dehydrogenase (Sigma, G4134) in
100 mM Tris-HCl (pH 7.4) for 60 min at
room temperature in the dark. DAN
reagent (100 µL) at 0.02 mg/mL concen-
tration in 248 mM HCl diluted from a
1.58 mg/mL stock in dimethyl for-
mamide was added, and the samples
were incubated for 30 min in the dark.
NaOH (40 µL of 2.8 M) was then added,
and the plate was analyzed on a fluores-
cent plate reader exciting at 360 ± 20 nm
and reading at 440 ± 20 nm.
Immunocytochemistry
Sections (40 µm thick) were cut from
fetal liver (e14 or p1) on a cryostat and
collected on gelatin-subbed slides. The
sections were washed twice in PBS (all
PBS solutions contained 0.01% thiomer-
sal) and treated with 50% ethanol at
room temperature for 30 min followed
by blocking with 10% normal goat serum
(NGS), 2% Triton X-100 in PBS for 3 h,
then incubated at 4°C for 94 h with rab-
bit anti-nNOS antibody (Zymed, cat. no.
Z-RNN3) at 0.25 µg/mL concentration.
Sections were washed four times with
PBS-T (PBS plus 1% Triton X-100) over a
period of 3 h at 4°C and then with PBS
with 4% NGS and 1% Triton X-100. Sec-
ondary antibody (Alexa fluor 594; Mole-
cular Probes) was applied at 5 µg/mL
for 3 h in PBS-T at 4°C, then sections
were washed with PBS-T for 3 h at room
temperature and overnight at 4°C. Fi-
nally, the sections were rinsed with
water, air dried, and mounted using
Prolong media (Molecular Probes). Con-
focal microscopy was performed on a
Zeiss LSM 510 machine using multi-
tracking, where excitation and emission
could not bleed through between chan-
nels. Optical slices (0.3 to 0.4 µm thick)
were collected that overlapped through
the entire section in the z-plane, so pro-
jections were continuous.
R E S E A R C H  A R T I C L E
M O L  M E D  1 4 ( 3 - 4 ) 1 4 1 - 1 4 9 ,  M A R C H - A P R I L  2 0 0 8  |  K R A S N O V  E T  A L .  |  1 4 3
RESULTS
Expression of NOS Isoforms in Stromal
Cells
We have previously shown that mRNA
of each NOS isoform can be detected in
bone marrow cells by RT-PCR (18). How-
ever, it was not known whether these
isoforms are expressed in the hematopoi-
etic or the stromal cells of the bone mar-
row. We have now compared NOS
mRNA expression in preparations of
cultured stromal and hematopoietic
cells from mouse bone marrow. nNOS
RNA expression levels were seven
times higher in stromal cells than in
hematopoietic cells, and for eNOS the
difference was 85 times; furthermore,
expression of NOS isoforms was higher
in stromal cells than in the preparation
of freshly isolated bone marrow, 1.4, 315,
and 39 times for nNOS, eNOS, and iNOS,
respectively (Figure 1A).
We also found that whereas the iNOS
protein, but not the other isoforms, can
be detected in the lysates of freshly iso-
lated bone marrow, high levels of eNOS
protein are detected in the bone marrow
and in stromal cells after cultivation
(Figure 1B). Low levels of eNOS and
iNOS can also be detected in hematopoi-
etic cells after cultivation (Figure 1B).
In agreement with the RNA and protein
analyses, we found that cultured stromal
cells but not bone marrow cells (isolated
and cultivated for 1 day) produced sig-
nificant amounts of NO (20 nmol total
nitrates/nitrites per 106 cells per day).
Together, these results indicate that stro-
mal cells of the bone marrow are the main
source of NOS mRNA, NOS protein, and
NO. They also suggest that stromal cells
may affect hematopoietic cells through
paracrine signaling by NO.
nNOS Is Expressed in the Fetal Liver
Fetal liver becomes the major site of
hematopoiesis in the mouse after embry-
onic day 11 (e11) and stays so until the
end of gestation, when hematopoiesis
switches over to bone marrow (36,37).
We compared the expression of NOS iso-
forms in the fetal liver at e14, immedi-
ately after birth (postnatal day 1, p1),
and in the adult liver. Expression of
nNOS mRNA was significantly higher in
e14 fetal liver than in p1 or adult liver
(3.7 and 5.5 times, respectively; Figure
2A). Also, levels of eNOS mRNA were
2.0 and 1.7 times higher in e14 and p1
liver compared with adult liver, whereas
for iNOS the difference was 0.5 and 0.1
times (Figure 2A).
We confirmed the expression of nNOS
in the fetal liver by immunocytochem-
istry: it was significantly higher at e14
than at p1 or in the adult liver (Figure 2B).
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Figure 1. NOS expression in bone marrow
cells. (A) Q-PCR analysis of NOS isoform ex-
pression. mRNA expression of each NOS
isoform was determined in cultured stromal
cells (SC) and hematopoietic cells (HC)
using Q-PCR and isoform-specific primers.
Data are presented as a ratio of expression
level of NOS isoform in stromal cells to that
in bone marrow. Data were analyzed using
t test; *P < 0.005, **P < 0.0001, #P < 0.005.
(B) Western blotting analysis of NOS isoform
expression. Lysates of bone marrow (BM),
primary bone marrow culture (PBMC), SC,
HC, human endothelial cells (HE), and brain
(BR) (latter two as control and reference)
were analyzed by electrophoresis and blot-
ting using antibodies against individual NOS
isoforms and β-actin (loading control).
Figure 2. NOS expression in the fetal liver.
(A) Fetal liver is enriched in nNOS. RNA ex-
pression of NOS isoforms was examined by
Q-PCR in liver at 14 days of embryonic de-
velopment (e14) and postnatal day 1 (p1)
and in adult liver. Data for each NOS iso-
form are presented as ratio of expression
level of NOS isoform in e14 and p1 liver to
that in adult liver. Data were analyzed using
t test; *P < 0.05, **P < 0.005, #P < 0.005.
(B) nNOS expression in the fetal liver. Expres-
sion of nNOS was determined in sections of
e14 (a), p1 (b), and adult (c) liver using
monoclonal antibodies against nNOS.
(d, e) Negative controls (omitting primary
antibody) for e14 (d) and adult (e) liver.
(C) Western blotting analysis of NOS iso-
form expression in the liver. Lysates of fetal
liver at embryonic day 14 (Fl-e14), fetal liver
at perinatal day 1 (Fl-p1), adult liver (AL),
human endothelial cells (HE), macrophage
(M), and brain (BR) (latter three as control
and reference) were analyzed by elec-
trophoresis and blotting using antibodies
against individual NOS isoforms.
These results were also confirmed using
the Western blot analysis of cell extracts
(Figure 2C). Furthermore, we found ac-
cumulation of nitrates/nitrites in cul-
tured e14 fetal liver cells (7 nmol total
nitrates/nitrites per 106 cells per day) but
not in cultured cells of the p1 liver (not
detectable). Together, these results dem-
onstrate that nNOS is expressed in the
fetal liver when this organ serves as the
major site of embryonic hematopoiesis,
but by birth, when bone marrow be-
comes the major site of hematopoiesis,
expression of nNOS in the liver is greatly
reduced.
Expression of nNOS Correlates with the
Supportive Abilities of Stromal Cell Lines
Hematopoietic stem cells are rapidly
depleted upon cultivation in vitro. Their
survival can be supported by cultivating
them with appropriate stromal cell lines.
Such supporting cell lines have been de-
rived from all of the major embryonic and
adult regions of definitive hematopoiesis-
embryonic aorta-gonads-mesonephros
(AGM) region, fetal liver, and adult bone
marrow (38-41). Among the derived cell
lines some, but not all, can support the
maintenance of repopulating hematopoi-
etic stem cells.
Because bone marrow stromal cells are
enriched in NOS RNA and protein and
nNOS is expressed in the e14 fetal liver,
we examined the relationship between
NOS expression and the ability of stro-
mal cells to support hematopoietic stem
cells. We examined the expression of
NOS isoforms in a panel of stromal cell
lines widely used to support cultures of
hematopoietic cells. Among them is a
group of four immortalized stromal cell
lines isolated from murine fetal liver
(38,39); these lines were generated as a
set, making comparisons between them
more straightforward. These cell lines
had been tested for their ability to sup-
port hematopoietic stem cells during
prolonged cultivation. Among this set is
a line (AFT024) that provides excellent
support for hematopoietic stem cells, a
line (2012) with limited supporting abili-
ties, and two lines (2018 and BFC) that
can support short- but not long-term
hematopoietic cells (38,39).
We were able to detect expression of
NOS isoforms in each of these fetal liver-
derived cell lines. Interestingly, expres-
sion of the nNOS mRNA correlated with
the ability of these cell lines to support
long-term hematopoietic stem cells: when
compared with bone marrow (taken as a
common standard in these experiments),
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Figure 3. Expression of nNOS correlates with the supporting ability of stromal cell lines.
(A) nNOS expression in a set of fetal liver-derived stromal cell lines with different supporting
capability for hematopoietic stem cells. mRNA expression for each NOS isoform was deter-
mined by Q-PCR. Data are presented as a ratio of expression level of NOS isoform in a
stromal line to that in murine bone marrow. Data were analyzed using t test; *P < 0.02.
(B) Western blotting analysis of NOS expression in fetal liver-derived stromal cell lines. Lysates
of stromal cells, bone marrow, and brain (as control and reference) were analyzed after
electrophoresis using antibodies against NOS isoforms. (C) LTC-IC assay. The number of
early hematopoietic progenitors was determined by cultivating hematopoietic cells on the
AFT024 stromal cell layer for 4 weeks and replating in methylcellulose for colony formation.
Data are presented as the number of LTC-IC per 1 × 104 bone marrow cells taken for analy-
sis. Data were analyzed using t test; *P < 0.02 (D) nNOS expression in selected stromal cell
lines. mRNA expression of NOS isoforms in several stromal lines differing in their ability to sup-
port hematopoietic stem cells and in cultured stromal cells from fetal liver (FLS) determined
by Q-PCR. Data are presented as a ratio of expression level of NOS isoform in a line to that
in murine bone marrow. Data were analyzed using t test; *P < 0.05, **P < 0.001.
nNOS levels in AFT024, 2012, 2018, and
BFC cells were, respectively, 1176, 7.5, 4.6,
and 0.5 times the levels in the bone mar-
row (Figure 3A). Expression of eNOS and
iNOS mRNA was also higher in the
AFT024 cells than in 2012, 2018, and BFC
cells, although the differences were much
smaller and the overall levels (compared
with bone marrow) were lower. Further-
more, nNOS protein was detected in
AFT024 cells but not in 2012, 2018, and
BFC cells (Figure 3B). To further examine
the role of NO in the ability of stromal
cells to support long-term hematopoietic
progenitors, we performed a LTC-IC
assay with cells cultivated on the AFT024
stromal cell layer with and without an
NO donor S-nitroso-N-acetyl-penicil-
lamine (SNAP) and determined the num-
ber of early hematopoietic progenitor
using the CFC assay. Addition of NO in-
creased the number of CFC colonies 3.5
times (Figure 3C), demonstrating that NO
helps to support early hematopoietic pro-
genitors during cultivation.
To further examine the potential rela-
tionship between NOS expression and the
supporting ability of stromal cell lines, we
analyzed a panel of stromal lines used as
a feeder layer for hematopoietic cell culti-
vation and established from adult bone
marrow [M2-10B4 (42) and S17 (43)], early
embryonic tissue (EL08, UG26, UG15,
AM20, and AM30 (40,41), and fetal (e14)
liver stroma [CFC034 (38)], as well as a
primary culture of cells isolated from the
fetal liver which also are capable of sup-
porting hematopoietic stem cells. We
found that those cell lines that have
been reported to effectively support
hematopoietic stem cells (M2-10B4,
EL08, and primary fetal liver cells) were
strongly enriched in nNOS mRNA (up to
400 times for the M2-10B4 line, compared
with bone marrow), whereas those that
did not support or had only poor to mod-
erate supporting abilities [UG15, AM20,
AM30, and S17 (39,41)] were not enriched
(Figure 3D). Interestingly, of the UG26-
UG15 pair, UG26 line (a good supporter)
expressed all three NOS isoforms at
higher levels than its UG15 counterpart
(a weaker supporter). Of further note,
CFC034 line was only two-fold enriched
in nNOS but had 20 times higher levels of
iNOS than bone marrow.
Together, these results demonstrate a
strong correlation between the hematopoi-
etic supporting ability of stromal cell lines
and the levels of expression of nNOS and
show that this ability can be increased by
the addition of NO. They further support
the idea that nNOS, produced by stromal
cells, may regulate hematopoietic cells in
a paracrine manner.
Hematopoiesis in nNOS-Knockout
Animals
We next examined the potential role of
NOS isoforms in hematopoiesis in more
detail, analyzing committed hematopoi-
etic progenitors (CFCs) in mice with inac-
tivated eNOS (44) and iNOS (45) genes,
as well as the nNOSKOex6-null mutant
mouse line (10); in these nNOS-knockout
mice, disruption of the heme-binding do-
main of nNOS results in a complete loss
of nNOS protein activity. We analyzed
the population of committed hematopoi-
etic progenitors by comparing the num-
bers of CFCs in the bone marrow and
spleen of wild-type and mutant animals.
We found a modest increase (1.4 times,
P < 0.05) in the number of CFCs in the
bone marrow of the iNOS-knockout mice
(both in frequency and in the total num-
ber of CFCs per femur), but did not see
significant differences in the bone mar-
row of the eNOS and nNOS knockouts
(Figure 4A). However, we found a strong
increase in the frequency (7.6 times, P <
0.05) and the total number (2.2 times, P <
0.05) of CFCs in the spleen of the nNOS-
knockout animals (Figure 4B).
We further examined the status of
hematopoietic progenitors by cultivating
cells from the bone marrow or spleen for
14 days in vitro and then testing them in
the CFC assay. Cultures from the bone
marrow of the nNOS-knockout mice
showed a 2.4-fold increase in the number
of CFCs compared with cultures from the
wild-type mice, whereas cultures from the
eNOS and iNOS knockouts produced the
same number of CFCs as the wild-type
controls (Figure 5A). Notably, cultures
from the spleens of the nNOS-knockout
mice produced 27.5 times more CFCs
than the wild-type controls (Figure 5A).
Furthermore, the increased number of the
CFCs in the cultures from the nNOS
knockouts was paralleled by a 2-fold (for
bone marrow) and an 18.2-fold (for
spleen) increase in the number of hemato-
poietic cells in cultures from the nNOS-
deficient animals (Figure 5B); in addition,
the number of stromal cells was increased
3.3-fold in cultures from spleens of the
nNOS knockouts (Figure 5C). Note that
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Figure 4. Hematopoietic progenitors in bone marrow and spleen of NOS-knockout mice.
Number of CFCs was determined for the bone marrow (BM) of wild-type (WT) and nNOS-,
eNOS-, and iNOS-knockout mice and in the spleen of wild-type and nNOS-knockout
mice. For each NOS knockout, data are presented as a ratio of frequency (number of
CFCs per 104 cells) (A) or total number of CFCs per femur in knockouts to those in wild-
type mice (B). Data were analyzed using t test; *P < 0.05.
whereas the number of CFC cells in the
wild-type or nNOS-deficient bone mar-
row decreased 11.6 and 5.1 times, respec-
tively, during cultivation (from 17,700 to
1500 and from 19,500 to 3800 per culture),
or stayed the same for the wild-type
spleen (600 vs. 700 per culture), the num-
ber of CFCs in cultured nNOS-deficient
spleen cells increased 4.4-fold (from 4400
to 19,300 per culture).
Together, the results with hematopoi-
etic progenitors from NOS mutant mice
indicate that reduction of NO production
results in an increased number of early
hematopoietic progenitors. In a converse
series of experiments, we found that ad-
dition of the NO donor SNAP results in a
dramatic decrease in the number of pro-
genitors to <3% of the control, when sub-
sequently probed using the CFC assay
(Figure 5D) (this was observed whether
calculated per culture or per 10,000 cells).
The results above suggest that the
stroma from nNOS-knockout animals
may be enriched in mesenchymal stem
cells. We measured these cells in the
CFC-F assay, comparing the bone mar-
row from the nNOS-deficient and wild-
type animals, and found 1.53 times more
CFC-Fs in the bone marrow of nNOS-
knockout than that of their wild-type
littermates (Figure 5E).
Together, these results demonstrate
that spleens from nNOS-deficient ani-
mals are enriched in committed colony-
producing progenitors (CFCs). Further-
more, they suggest that bone marrow
and spleen of nNOS knockouts are en-
riched in less mature CFC precursor
cells or may provide a better support
for the cultivation and maintenance of
hematopoietic cells in vitro.
DISCUSSION
We present evidence that NO, pro-
duced in stromal cells by nNOS, may
act as a paracrine effector to regulate
hematopoiesis in the bone marrow and
spleen. We show that mRNA of all NOS
isoforms is produced in bone marrow
stromal cells and that nNOS, in particu-
lar, is expressed in bone marrow stroma,
fetal liver, and fetal liver-derived cell
lines. We further show that expression of
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Figure 5. Hematopoietic progenitors and mesenchymal stem cells in the NOS knockouts. Number of CFCs (A), hematopoietic cells (B),
and stromal cells (C) per culture after cultivation of bone marrow cells from wild-type (WT) and NOS-knockout mice and spleen cells
from wild-type and nNOS knockouts. Data are presented as a ratio of colonies or cells per culture in knockouts to those in wild-type
mice. Data were analyzed using t test; *P < 0.05. (D) Addition of SNAP during cultivation decreases the number of hematopoietic pro-
genitors. Bone marrow cells were cultivated in the Myelocult media with or without 250 µM SNAP for the indicated number of days, and
the number of committed progenitors was determined using the CFC assay. The data are presented as a ratio of colonies per 104 cells
after cultivation to the number of colonies in the starting culture (input), i.e., determined at day 0. Similar results were obtained when the
CFC number per culture was calculated. Data were analyzed using t test; *P < 0.01, **P < 0.001, #P < 0.01, ##P < 5 × 10-7. (E) Number of
CFC-Fs per 0.5 × 106 cells in the bone marrow of wild-type and nNOS-knockout mice. Data were analyzed using t test; *P < 0.05.
nNOS correlates with the ability of a set
of stromal cell lines to support long-term
hematopoietic stem cells and that addi-
tion of an NO donor increases this abil-
ity; furthermore, several other stromal
cell lines, widely used to maintain
hematopoietic stem cells in culture, ex-
press high levels of nNOS. This potential
role of nNOS in regulating hematopoiesis
is confirmed in our experiments with
mutant animals, where inactivation of
the nNOS gene results in an increased
number of committed progenitors
(CFCs) in the spleen and, upon further
cultivation of cells, in a greatly in-
creased number of CFCs in the spleen
and the bone marrow.
Together, our data suggest a model in
which NO, produced by nNOS in the
stromal cells of the bone marrow and
spleen, acts in a paracrine manner to
negatively control hematopoiesis. This
model is compatible with the observa-
tions that NO can act as a negative regu-
lator of hematopoietic stem and progeni-
tor cells in vitro and in vivo. Donors of
NO can change the extent of hematopoi-
etic maturation in vitro (26,29), and 
inhibitors of NOS activity affect the ac-
tion of TNFα, IFNγ, and GM-CSF on
hematopoiesis in vitro (26-29). Impor-
tantly, we have shown that NO regulates
hematopoietic stem and early progenitor
cell activity in vivo such that treatment
with NOS inhibitors increase the number
of stem cells in the bone marrow (18). We
posit that the experiments with the NO
donors and the NOS inhibitors reflect
the action of the stroma-derived NO on
hematopoietic cells in the bone marrow.
In each case, NO arises as a negative reg-
ulator of hematopoietic stem and pro-
genitor cells, such that suppression of
NOS activity increases the number of
hematopoietic cells in vitro and in vivo.
A putative regulatory role for NO may
be related to the microenvironment of
hematopoietic stem cells (46). The stem
cell niche in bone marrow is hypoxic, and
analysis of the proteome of hematopoietic
stem cells shows adaptation for an anaer-
obic environment, including increased ex-
pression of antioxidant enzymes (47).
Hematopoietic stem cells are highly sen-
sitive to reactive oxygen species (ROS)
(46,48,49), and nNOS-produced NO, a
potent antioxidant, may contribute to the
defense against ROS by scavenging su-
peroxides, preventing heme oxidation,
suppressing Fenton chemistry, and atten-
uating lipid peroxidation (7,15,17); fur-
thermore, NO controls expression of a
wide range of cell-protective and antipro-
liferative genes (50-52). Notably, post-
translational control plays a prominent
role in regulating hematopoietic stem
cells in their hypoxic niche (47), and
nNOS may be particularly well suited for
controlling the niche because it is upregu-
lated by hypoxia; moreover, chronic hy-
poxia induces a translationally efficient
isoform of nNOS mRNA that is resistant
to the global translational repression in-
duced by hypoxia (53). Furthermore, NO
increases the expression of angiopoietin 1
and its receptor Tie2 (54), whose interac-
tions are crucial for maintaining the qui-
escence of hematopoietic stem cells in the
bone marrow niche (55). Overall, the
functional role of NO in hematopoietic
tissues may be to act as an antioxidant
and to establish a dominant antiprolifera-
tive tone to help protect the stem cell
pool from premature depletion when
challenged with stressful stimuli (18,56).
Such a role for NO is compatible with the
expression of nNOS in the supporting
stromal lines derived from fetal liver and
adult bone marrow (sites of definitive
hematopoiesis); in these tissues, their
ability to maintain hematopoietic stem
cells rather than simply to induce them
(as in the yolk sac or AGM, the sources of
primitive hematopoietic stem cells), be-
comes of paramount importance, and
nNOS may play a significant role in this
regulatory step.
There are several other possible links
between NO and hematopoiesis, includ-
ing its potential to regulate proteolysis
and to affect mobilization of hematopoi-
etic stem cells (25,57). Whereas the role
of eNOS (most probably, produced by
endothelial cells) in mobilization of
hematopoietic stem cells has been con-
vincingly demonstrated (25), the some-
what unexpected role of nNOS may have
been overlooked so far. Selective inacti-
vation of the nNOS gene in stromal cells
may provide further evidence for the im-
portance of the paracrine signaling by
NO for hematopoiesis.
The regulatory function of NO in the
bone marrow and fetal liver that we
found may parallel the role of NO in the
developing and adult brain (10,13,14,58),
where suppression or upregulation of
nNOS activity results in an increase or a
decrease, respectively, in neurogenesis. It
will be important to determine whether
NO uses the same molecular mecha-
nisms to control neurogenesis and
hematopoiesis.
In addition to revealing a link between
NO and hematopoiesis, our results point
to nNOS as a possible pharmacological
target and suggest that nNOS-selective
inhibitors may have a therapeutic poten-
tial for hematopoiesis-related disorders.
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